The purpose of this scoping review is to describe and summarise the rationale behind and methodological approaches used to conduct cascade-of-care analyses for TB infection in low-TB incidence countries.
This report provides an overview of the latest tuberculosis (TB) epidemiological situation and is published jointly by the WHO Regional Office for Europe and the European Centre for Disease Prevention and Control.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
In 2022, the first and second most reported zoonoses in humans were campylobacteriosis and salmonellosis, respectively. The number of cases of campylobacteriosis and salmonellosis remained stable in comparison with 2021.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
For 2021, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 33 527 tuberculosis (TB) cases (7.4 per 100 000 population).